









市场行情
/
股票
/
nasdaq-sttk
/

Shattuck Labs Inc

STTK

3.140USD

-0.010-0.32%

收盘 12/22, 16:00（美东）报价延迟15分钟

198.30M总市值

亏损市盈率 TTM



Shattuck Labs Inc

3.140

-0.010-0.32%

概览公司财务分析

概览

公司

财务

分析

关于 Shattuck Labs Inc 公司

Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Shattuck Labs Inc简介



公司代码STTK

公司名称Shattuck Labs Inc

上市日期Oct 09, 2020

CEOSchreiber (Taylor)

员工数量44

证券类型Ordinary Share

年结日Oct 09

公司地址500 W. 5Th Street

城市AUSTIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编78701

电话15129004690

网址https://www.shattucklabs.com/

公司代码STTK

上市日期Oct 09, 2020

CEOSchreiber (Taylor)

Shattuck Labs Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Taylor Schreiber, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Director

96.61K

+36.07%

Dr. Stephen Stout, Ph.D.

General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer

86.28K

+17.43%

Ms. Casi Deyoung

Chief Business Officer

81.47K

-8.97%

Dr. George S. Golumbeski, Ph.D.

Independent Chairman of the Board

54.61K

Dr. Neil W. Gibson ,Ph.D.

Independent Director

52.74K

Ms. Helen M. Boudreau

Independent Director

Mr. Conor Richardson, CPA

Senior Director, Finance & Investor Relations

Dr. Clay Siegall, Ph.D.

Independent Director

Mr. Andrew R. Neill

Chief Financial Officer

Dr. Abhinav A. Shukla, Ph.D.

Chief Technical Officer

名称

名称/职务

职务

持股

持股变动

Dr. Taylor Schreiber, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Director

96.61K

+36.07%

Dr. Stephen Stout, Ph.D.

General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer

86.28K

+17.43%

Ms. Casi Deyoung

Chief Business Officer

81.47K

-8.97%

Dr. George S. Golumbeski, Ph.D.

Independent Chairman of the Board

54.61K

Dr. Neil W. Gibson ,Ph.D.

Independent Director

52.74K

Ms. Helen M. Boudreau

Independent Director

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

OrbiMed Advisors, LLC

9.97%

Adage Capital Management, L.P.

9.97%

Redmile Group, LLC

8.75%

Prosight Capital

8.61%

Hornblower Capital Holdings, LLC

4.57%

其他

58.13%

持股股东

占比

OrbiMed Advisors, LLC

9.97%

Adage Capital Management, L.P.

9.97%

Redmile Group, LLC

8.75%

Prosight Capital

8.61%

Hornblower Capital Holdings, LLC

4.57%

其他

58.13%

股东类型

持股股东

占比

Hedge Fund

23.34%

Investment Advisor/Hedge Fund

14.04%

Private Equity

9.97%

Corporation

9.51%

Investment Advisor

4.87%

Family Office

2.58%

Research Firm

2.11%

Individual Investor

1.85%

Venture Capital

0.04%

其他

31.69%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

179

32.72M

51.71%

-1.24M

2025Q2

186

35.33M

73.76%

-6.35M

2025Q1

190

36.10M

75.45%

-5.76M

2024Q4

182

37.00M

77.49%

-7.77M

2024Q3

191

41.87M

87.75%

-1.86M

2024Q2

194

39.66M

83.35%

+16.66K

2024Q1

209

37.10M

79.60%

-1.39M

2023Q4

203

34.54M

71.04%

+5.75M

2023Q3

205

27.35M

64.28%

-7.93M

2023Q2

215

27.61M

64.91%

-8.42M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

OrbiMed Advisors, LLC

6.31M

13.16%

+6.31M

Sep 02, 2025

Adage Capital Management, L.P.

4.67M

9.76%

Jun 30, 2025

Redmile Group, LLC

5.54M

11.56%

Aug 25, 2025

Prosight Capital

6.64M

13.86%

Jun 30, 2025

Hornblower Capital Holdings, LLC

2.89M

6.04%

Apr 01, 2025

Houghton Capital Holdings, LLC

2.61M

5.45%

Apr 01, 2025

The Vanguard Group, Inc.

2.15M

4.48%

-252.36K

-10.51%

Jun 30, 2025

683 Capital Management LLC

1.09M

2.29%

+45.00K

+4.29%

Jun 30, 2025

The Clark Estates Inc.

1.48M

3.08%

Jun 30, 2025

Pinnacle Associates Ltd.

1.36M

2.85%

+64.00K

+4.92%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Texas Capital Texas Equity Index ETF

iShares Russell 2000 Value ETF

ProShares UltraPro Russell2000

Dimensional US Core Equity 1 ETF

ProShares Hedge Replication ETF

iShares Morningstar Small-Cap ETF

iShares Russell 2000 ETF

Avantis US Small Cap Equity ETF

iShares Micro-Cap ETF

Texas Capital Texas Small Cap Equity Index ETF

Texas Capital Texas Equity Index ETF

占比0%

iShares Russell 2000 Value ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Dimensional US Core Equity 1 ETF

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Morningstar Small-Cap ETF

占比0%

iShares Russell 2000 ETF

占比0%

Avantis US Small Cap Equity ETF

占比0%

iShares Micro-Cap ETF

占比0%

Texas Capital Texas Small Cap Equity Index ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Shattuck Labs Inc的前五大股东是谁？



Shattuck Labs Inc 的前五大股东如下：
OrbiMed Advisors, LLC持有股份：6.31M，占总股份比例：13.16%。
Adage Capital Management, L.P.持有股份：4.67M，占总股份比例：9.76%。
Redmile Group, LLC持有股份：5.54M，占总股份比例：11.56%。
Prosight Capital持有股份：6.64M，占总股份比例：13.86%。
Hornblower Capital Holdings, LLC持有股份：2.89M，占总股份比例：6.04%。